Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $67.00 Price Target at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price hoisted by investment analysts at Cantor Fitzgerald from $63.00 to $67.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 35.76% from the company’s previous close.

Several other research firms have also commented on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Down 2.2%

NASDAQ SUPN traded down $1.09 on Thursday, reaching $49.35. 270,039 shares of the company were exchanged, compared to its average volume of 729,182. The business’s fifty day moving average price is $47.10 and its 200 day moving average price is $49.51. The stock has a market capitalization of $2.86 billion, a P/E ratio of -96.76, a price-to-earnings-growth ratio of 1.02 and a beta of 0.54. Supernus Pharmaceuticals has a fifty-two week low of $32.20 and a fifty-two week high of $59.68.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its position in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at $49,000. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the period. Global Retirement Partners LLC grew its stake in Supernus Pharmaceuticals by 532.4% during the 4th quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 1,182 shares in the last quarter. Finally, Vestcor Inc acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth $67,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.